

**Date:** 16<sup>th</sup> & 17<sup>th</sup> December 2013

**Minutes:** Final

**Guideline Development Group Meeting 7**      **Type 2 Diabetes**

**Place:** *Floor 24*  
*Red Rooms*  
*Piccadilly Plaza*  
*Manchester*

**Present:** Damien Longson (Chair)  
Natasha Jacques (NJ)  
Anne Fittock (AF)  
Ian Lewin (IL)  
Sailesh Sankar (SS)  
Maria Cowell (MC)  
Jonathan Roddick (JR)  
Yvonne Johns (YJ)  
Natasha Marsland (NM)  
Prunella Neale (PN)  
Indranil Dasgupta (ID) – co-opted expert  
Amanda Adler (AA)

**Apologies:** Amanda Adler (AA) (16<sup>th</sup> December only)  
Natasha Marsland (NM) (17<sup>th</sup> December only)  
Andrew Farmer (AF)

**In attendance:**

**NICE Staff:**

Abitha Senthinathan (AS)  
Stephanie Mills (SM)  
Mike Heath (MH)  
Steven Ward (SWard)  
Gabriel Rogers (GR)  
Clifford Middleton (CM)  
Toni Tan (TT)  
Sarah Palombella (SP)  
Sheryl Warttig (Sw)

**Observers:**

Sheryl Warttig – NICE Staff (also observing)		
Charlotte Purves – NICE Staff		
Kathryn Hopkins – NICE Staff		

## **Day 1 – 16<sup>th</sup> Dec 2013**

1. DL welcomed the group to the seventh meeting of this GDG. Apologies were received from AA, AF, and NM. The group declared that they knew of no personal specific, personal non-specific, non-personal specific or non-personal non-specific interest in the development of this guideline beyond those which had previously been declared.

DL asked whether the group agreed that the minutes of the previous meeting were a clear and accurate record. The minutes were agreed by all with a minor grammatical amendment to be made. The GDG heard that the objectives of the meeting would be to recap on learning about network meta-analysis (NMA) and reading NMA results, be presented with initial results for initial pharmacological therapy, hear more about the progress on health economic modelling and revisit the discussion on target values for HbA1c.

There was no update on the diabetes oversight group (DOG), with the next DOG meeting to be conducted in the January 2014.

2. AS began the meeting by explaining NMA and demonstrating the types of numeric and pictorial results the GDG could expect to be presented with.

AS presented the draft results for the NMA's that had been conducted so far.

3. Following this session, SW was able to present the review protocol for question 2 on long term safety issues of pharmacological agents. The GDG described some of the key words and events SW should look for in the study literature. The group also considered outcomes and what might be considered critical or important based on GRADE methodology.
4. SM gave a short presentation on the guideline structure for CG66 and what is likely to happen for those areas not being updated within this current guideline update.
5. SWard gave an update on the progress with the modelling for type 2 diabetes. The GDG offered their views on what would be a sensible approach for the health economists to take.
6. DL thanked the group for the hard work on day 1. SM let the group know that the meeting would begin at 9:30am on 17<sup>th</sup> December and would be held in the same building.

## **Day 2 – 17<sup>th</sup> December 2013**

7. Having got through much of the content of the GDG meeting on day 1, DL introduced the primary aim of day 2 would be to agree the HbA1c target values based on the review questions 3 and 4 in the guideline scope.
8. RR re-presented a small chunk of important data from the evidence review for questions 3 and 4 to aid GDG decision-making. The GDG were shown the recommendations that they had produced at the previous meeting and were asked to consider these alongside the recommendations on target values from CG66 and CG87.
9. SM thanked the group for their input and confirmed when the next meetings in development of the guideline would be.

**Date, time and venue of the next meeting**

Tues 4<sup>th</sup> March 2014 –NICE Offices, Manchester